Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) / Wei, Andrew H.; Breccia, Massimo; Ooi, Melissa; Romero, Maria Teresa Cedena; Ciceri, Fabio; Erba, Harry P.; Gaur, Anil; Sechaud, Romain; Halilovic, Ensar; Kuenzle, Brigitte; Fabre, Claire; Porkka, Kimmo. - In: BLOOD. - ISSN 0006-4971. - 138:1(2021). [10.1182/blood-2021-144650]
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
Breccia, Massimo;
2021
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
